Excell Clinical Laboratory, INC.

Excell Clinical Laboratory, INC. was paid $1.96M by Medicaid between Jan 2018 and Dec 2024, across 107 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 39% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#53 of 122

Median peer was paid$1.29M

This provider vs. median1.5×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	8,550	$115K
2019	14,419	$208K
2020	28,473	$336K
2021	54,778	$508K
2022	81,734	$526K
2023	64,790	$156K
2024incomplete	48,915	$112K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	39%	17,897	8,602	$771K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	29%	8,160	5,992	$578K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	10%	23,719	9,564	$205K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	4.6%	18,928	7,572	$90K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	2.7%	3,497	2,364	$53K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.8%	10,089	7,629	$35K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	1.6%	725	556	$31K
80061	Lipid panel	1.2%	15,912	13,108	$23K
82607		<1%	8,789	6,074	$18K
80053	Comprehensive metabolic panel	<1%	17,457	14,480	$14K
84443	Thyroid stimulating hormone (TSH)	<1%	11,884	10,116	$13K
80050	General health panel	<1%	944	560	$13K

95 more codes

83036	Hemoglobin; glycosylated (A1C)	<1%	14,919	$11K
82746		<1%	6,134	$9K
84153		<1%	3,020	$7K
82728		<1%	4,116	$7K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	656	$6K
86141		<1%	1,713	$6K
84480		<1%	3,635	$5K
84439		<1%	4,048	$5K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	17,600	$5K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	8,199	$5K
86376		<1%	463	$4K
86769		<1%	664	$3K
84481		<1%	872	$3K
83550		<1%	4,519	$3K
83735		<1%	4,248	$2K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	10,149	$2K
81001		<1%	9,187	$2K
84436		<1%	4,182	$2K
83540		<1%	4,594	$2K
82043		<1%	4,864	$2K
86703		<1%	406	$2K
84479		<1%	2,921	$2K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	331	$2K
87086	Culture, bacterial; quantitative colony count, urine	<1%	3,113	$1K
87481		<1%	341	$1K
82570		<1%	4,880	$1K
84550		<1%	2,628	$1K
36415	Collection of venous blood by venipuncture	<1%	17,951	$1K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	59	$821.30
85045		<1%	1,215	$775.74
84403		<1%	364	$730.83
83880		<1%	511	$721.92
86803		<1%	395	$597.80
85651		<1%	4,043	$584.93
80361		<1%	150	$560.00
80358		<1%	148	$545.00
80348		<1%	148	$545.00
80364		<1%	145	$540.00
80367		<1%	139	$525.00
80048	Basic metabolic panel (calcium, ionized)	<1%	1,071	$504.15
86140		<1%	2,177	$472.08
82248		<1%	1,138	$443.37
86431		<1%	673	$437.36
84402		<1%	287	$433.63
86038		<1%	591	$425.15
86618		<1%	45	$388.43
87077		<1%	693	$378.27
86617		<1%	14	$342.60
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	320	$329.20
87653		<1%	343	$307.70
87088		<1%	794	$293.01
87641		<1%	297	$286.27
80350		<1%	82	$285.00
82550		<1%	583	$281.99
84207		<1%	12	$277.52
86706		<1%	282	$262.05
83785		<1%	12	$242.96
87186		<1%	431	$200.85
80074		<1%	12	$185.29
85610		<1%	2,141	$156.30
84466		<1%	216	$145.08
84446		<1%	12	$140.08
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	1,004	$137.93
84100		<1%	956	$135.08
87340		<1%	84	$124.91
84425		<1%	12	$120.00
84590		<1%	12	$114.64
87581		<1%	62	$109.48
87486		<1%	63	$109.48
82270		<1%	82	$93.11
80349		<1%	21	$90.00
84252		<1%	12	$90.00
82180		<1%	13	$82.80
80356		<1%	19	$75.00
84630		<1%	13	$63.20
87500		<1%	52	$56.14
84154		<1%	28	$54.70
80365		<1%	15	$50.00
82977		<1%	28	$35.58
86592		<1%	428	$31.54
84146		<1%	36	$27.14
80164		<1%	47	$10.00
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	45	$6.67
82985		<1%	18	$6.60
86060		<1%	17	$3.60
87640		0%	30	$0.00
87556		0%	30	$0.00
83615		0%	16	$0.00
80372		0%	142	$0.00
83970		0%	13	$0.00
87563		0%	30	$0.00
82652		0%	14	$0.00
80354		0%	150	$0.00
80369		0%	130	$0.00
80373		0%	140	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBELOTSERKOVSKY, MARINA (PRESIDENT)